|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
70,267,000 |
Market
Cap: |
2.31(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.61 - $51.88 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1144 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
353,560 |
353,560 |
370,420 |
Total Sell Value |
$0 |
$12,092,086 |
$12,092,086 |
$12,714,697 |
Total People Sold |
0 |
7 |
7 |
8 |
Total Sell Transactions |
0 |
11 |
11 |
12 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Crowley Elizabeth |
Sr. VP &CPDO |
|
2021-12-08 |
4 |
OE |
$9.02 |
$36,066 |
D/D |
4,000 |
8,726 |
|
- |
|
Martin Samuel Bates |
SVP and CFO |
|
2021-11-15 |
4 |
AS |
$42.27 |
$413,883 |
D/D |
(9,500) |
26,878 |
|
- |
|
Martin Samuel Bates |
SVP and CFO |
|
2021-11-15 |
4 |
OE |
$2.78 |
$39,729 |
D/D |
7,000 |
36,378 |
|
- |
|
Young Diane C. |
SVP, Chief Medical Officer |
|
2021-11-12 |
4 |
S |
$42.94 |
$197,529 |
D/D |
(4,600) |
2,115 |
|
- |
|
Young Diane C. |
SVP, Chief Medical Officer |
|
2021-11-12 |
4 |
OE |
$10.38 |
$47,748 |
D/D |
4,600 |
6,715 |
|
- |
|
Cavanaugh Sarah |
SVP of Corp Affairs & Admin. |
|
2021-11-01 |
4 |
AS |
$41.62 |
$316,804 |
D/D |
(7,323) |
408 |
|
- |
|
Cavanaugh Sarah |
SVP of Corp Affairs & Admin. |
|
2021-11-01 |
4 |
OE |
$2.78 |
$47,852 |
D/D |
5,956 |
7,731 |
|
- |
|
Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
|
2021-11-01 |
4 |
AS |
$41.71 |
$25,026 |
D/D |
(600) |
11,247 |
|
- |
|
Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
|
2021-11-01 |
4 |
OE |
$2.78 |
$1,668 |
D/D |
600 |
11,847 |
|
- |
|
Crowley Elizabeth |
Sr. VP &CPDO |
|
2021-11-01 |
4 |
AS |
$41.62 |
$186,874 |
D/D |
(4,317) |
4,726 |
|
- |
|
Crowley Elizabeth |
Sr. VP &CPDO |
|
2021-11-01 |
4 |
OE |
$2.78 |
$23,783 |
D/D |
8,555 |
9,043 |
|
- |
|
Jimenez Freddy A. |
SVP & General Counsel |
|
2021-08-11 |
4 |
B |
$46.28 |
$19,900 |
D/D |
430 |
430 |
2.74 |
- |
|
Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
|
2021-08-11 |
4 |
OE |
$9.02 |
$90,165 |
D/D |
10,000 |
11,247 |
|
- |
|
Martin Samuel Bates |
SVP and CFO |
|
2021-08-10 |
4 |
S |
$45.25 |
$123,895 |
D/D |
(2,738) |
29,378 |
|
- |
|
Martin Samuel Bates |
SVP and CFO |
|
2021-08-10 |
4 |
OE |
$2.78 |
$123,688 |
D/D |
21,381 |
30,060 |
|
- |
|
Marucci Anthony S |
President & CEO |
|
2021-08-05 |
4 |
OE |
$42.00 |
$148,554 |
D/D |
3,537 |
27,231 |
|
- |
|
Wright Richard M. |
Sr. VP & CCO |
|
2020-12-14 |
4 |
S |
$18.61 |
$387,611 |
D/D |
(20,832) |
208 |
|
- |
|
Wright Richard M. |
Sr. VP & CCO |
|
2020-12-14 |
4 |
OE |
$2.78 |
$129,365 |
D/D |
20,832 |
9,583 |
|
- |
|
Young Diane C. |
SVP, Chief Medical Officer |
|
2020-06-11 |
4 |
B |
$4.73 |
$10,004 |
D/D |
2,115 |
2,115 |
2.74 |
- |
|
Cavanaugh Sarah |
SVP of Corp Affairs & Admin. |
|
2020-06-10 |
4 |
B |
$4.83 |
$5,072 |
D/D |
1,050 |
1,367 |
2.74 |
- |
|
Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
|
2020-06-09 |
4 |
B |
$3.01 |
$3,005 |
D/D |
1,000 |
1,000 |
2.66 |
- |
|
Keler Tibor |
Executive VP & CSO |
|
2020-06-09 |
4 |
B |
$2.99 |
$14,954 |
D/D |
5,000 |
7,357 |
2.74 |
- |
|
Marucci Anthony S |
President & CEO |
|
2020-06-09 |
4 |
B |
$3.06 |
$45,900 |
D/D |
15,000 |
19,438 |
2.81 |
- |
|
Martin Samuel Bates |
SVP and CFO |
|
2020-06-09 |
4 |
B |
$3.05 |
$29,738 |
D/D |
9,750 |
10,735 |
2.74 |
- |
|
Marino James J |
Director |
|
2020-06-09 |
4 |
B |
$3.00 |
$24,915 |
D/D |
8,305 |
12,704 |
2.39 |
- |
|
121 Records found
|
|
Page 2 of 5 |
|
|